DV
Dividend Vision

ADIL — Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc (ADIL)

Total return is -99.8% over the past 8 years, 311.4 points behind SPY at 211.6%. Its deepest 1-year drawdown was 87.0%.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders, with its lead candidate AD04 currently in Phase 3 clinical trials for alcohol use disorder treatment. The company does not currently distribute dividends. As a pre-revenue clinical-stage biotech company, it appeals to investors seeking exposure to early-stage pharmaceutical development rather than current income generation.

ADIL key facts

Asset type
Stock
Asset class
Equity
Inception date
07/27/2018
Last close
$3.98
Market cap
$6,127,713
Average volume
48600.0
Beta
1.432
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.89